Previous studies indicated that CCL23 is a progressive biomarker for the diagnosis of brain lesions such as Alzheimer’s disease and ischemic stroke, and circulating CCL23 levels were reported to function as biomarkers of outcomes in the aforementioned patients, and consequently influence the management and treatment decisions of these patients [10–12]. Here, CCL23 is linked to early-onset autosomal dominant Alzheimer disease.